Elite in Friedreich Ataxia

Paola Giunti

UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
Elite in Friedreich Ataxia
UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Paola Giunti practices in London, United Kingdom. Ms. Giunti is rated as an Elite expert by MediFind in the treatment of Friedreich Ataxia. Her top areas of expertise are Friedreich Ataxia, Spinocerebellar Ataxia, Drug Induced Dyskinesia, and Hereditary Ataxia.

Her clinical research consists of co-authoring 151 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 48 articles and participated in 2 clinical trials in the study of Friedreich Ataxia.

Gender
Female

Locations

UCL Queen Square Institute Of Neurology, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drug: Omaveloxolone
Study Phase: Phase 2
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Enrollment Status: Completed
Publish Date: October 03, 2025
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3
Enrollment Status: Terminated
Publish Date: August 04, 2023
Intervention Type: Drug
Study Drug: BIIB132
Study Phase: Phase 1
View 2 Less Clinical Trials

151 Total Publications

Progress and challenges in sporadic late-onset cerebellar ataxias.
Progress and challenges in sporadic late-onset cerebellar ataxias.
Journal: Nature reviews. Neurology
Published: August 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Giunti's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile